PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations
FAP-targeted molecular radiotherapy in cancer patients
FAP-targeted PET imaging in cancer patients
Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC
METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours
Real-world increase in biomarker testing in lung cancer
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408
Survival outcomes of unilateral RB based on pathological risk stratification-experience at a tertiary care centre in Pakistan
Cancer nursing in India: Febrile neutropenia
Cancer nursing in India: Tumour lysis syndrome
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion